NO.1 Support qualified traditional Chinese medicine and other biopharmaceutical companies to issue and list on the Shanghai and Shenzhen stock exchanges

The China Securities Regulatory Commission has issued a letter in response to Proposal No. 4171 (Finance, Taxation, and Finance 261) of the Second Session of the 14th National Committee of the Chinese People's Political Consultative Conference. Among them, it is mentioned that actively supporting qualified biopharmaceutical companies, including traditional Chinese medicine, to issue and list on the Shanghai and Shenzhen stock exchanges, focusing on expanding direct financing channels for biopharmaceutical companies, and fully leveraging the supportive role of the capital market in the development of the biopharmaceutical industry.

Commentary: The China Securities Regulatory Commission supports the listing of traditional Chinese medicine and other biopharmaceutical companies, expanding direct financing channels. This move will help promote innovative development in the biopharmaceutical industry, enhance the support of the capital market for the real economy, and promote the optimization and upgrading of the industrial structure.

No.2 Chengdu Pioneer Discloses Shareholders' Share Reduction Plan

Chengdu Pioneer disclosed its shareholder reduction plan, which includes Anji Dongfang Jiayu Enterprise Management Partnership (Limited Partnership), Shenzhen Juntian Investment Enterprise (Limited Partnership), and Lhasa Economic and Technological Development Zone Huabo Medical Equipment Co., Ltd., all of which were acquired before the company's IPO.

Comment: This move may affect the market's confidence in the company's short-term stock price, reflecting shareholders' expectations or funding needs for the company's future development.

NO.3 Shanghai Pharmaceutical Discloses Progress on Acquisition and 10% Equity of Huang Pharmaceutical

Shanghai Pharmaceutical disclosed the progress of the acquisition and the 10% equity of Huang Pharmaceutical. The progress of this transaction mainly clarifies that the designated entities of Jinpu Jianfu are Jinpu Fund and Zhibai He Enterprise Management, and modifies the corresponding statements in the agreement regarding Jinpu Jianfu and the 35% equity transaction, which does not have a substantial impact on Shanghai Pharmaceutical's rights and obligations.

Comment: This acquisition is an important capital operation for Shanghai Pharmaceuticals, which helps it consolidate its position in the fierce market competition and also provides investors with new growth expectations.

NO.4 Shenzhou cell anti-PD-1 monoclonal antibody combination therapy approved

The official website of China National Medical Products Administration (NMPA) announced that the marketing authorization application for the combination therapy of Firmab Injection (SCT-I10A) and Bevacizumab Injection (SCT510) submitted by Shenzhou Cell Engineering, a subsidiary of Shenzhou Cell, has been approved. According to a previous press release released by Shenzhou Cell, the approved indication for this drug is: for patients with unresectable or metastatic hepatocellular carcinoma who have not received systematic treatment in the past.

Commentary: Hepatocellular carcinoma (HCC), as the main subtype of liver cancer, accounts for 85% to 90% of primary liver cancer. HCC has a high degree of malignancy, and existing treatment methods cannot meet the long-term survival benefits. There is still a huge unmet clinical need. This therapy is expected to bring new therapeutic explorations.

NO.5 Amycritin Injection Approved for Clinical Use in China

According to the official website of CDE, Novo Nordisk's Class 1 new drug Amycritin Injection has been approved for clinical use and is intended to be developed for reducing the weight of overweight or obese adult patients. This is the first time that the injection form of the drug has been approved for clinical use in China. Previously, the tablet form of this product had been approved for clinical use in China to reduce the weight of overweight or obese adult patients.

Comment: Existing weight loss drugs are facing an increasingly fierce competitive environment, and Amycritin injection has been approved for clinical use in China, which is of great significance to Novo Nordisk.

Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before use. Based on this operation, the risk is borne by oneself.